Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis

What Was Tested

The paper reports a study of Teriparatide in the context of osteoporosis and bone density, published as a randomized controlled trial.

The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

General linear model-repeated measurements were used to analyze the data.

How the Study Was Run

The design is described as randomized.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months.

What Was Measured

Topics PubMed links to this paper include Acid Phosphatase, Biomarkers, Bone Density, Bone Density Conservation Agents, Calcium, Collagen Type I and Isoenzymes.

What This Means in Plain Language

The paper is a randomized study of Teriparatide in people with osteoporosis and bone density.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.